VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
The first was led by Apricot Capital, a local healthcare investor founded in 2015 that has more than RMB3 billion ($463 million) in assets under management. The second came from Loyal Valley Capital and...
More on Greater China
Latest News
True North exits India's RDC Concrete after 16-year hold
True North has agreed to sell India-based RDC Concrete, a company it has owned since 2005, to private equity-backed online construction marketplace Infra.market.
India's Freshworks flourishes on NASDAQ debut
Freshworks, one of India's leading software-as-a-service (SaaS) businesses, traded strongly on its NASDAQ debut following a $1 billion IPO.
FountainVest buys New Zealand pet food business
China-focused private equity firm FountainVest Partners has agreed to buy Ziwi, New Zealand’s leading exporter of pet food.